BioSpace News Archive

Drug Development

Novartis’ Iptacopan Aces Phase III Study in Ultra-Rare Kidney Disease Days After FDA Approval

The trial demonstrated that C3G glomerulopathy patients treated with the oral factor B inhibitor saw a significant reduction in protein in their urine. The results come days after iptacopan won the FDA’s green light for a rare blood disease.

December 12, 2023
·
2 min read
·
Tristan Manalac
Business

BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast Cancer

Bristol Myers Squibb has bought the rights to develop and commercialize SystImmune’s potentially first-in-class, bi-specific antibody-drug conjugate for lung and breast cancer as well as other solid tumors.

December 12, 2023
·
2 min read
·
Tristan Manalac
Deals

Pfizer’s $43B Seagen Buy Clears Regulatory Hurdles, Plans Dec 14 Closing

The companies have received all required regulatory approvals to complete the deal, the largest for the sector in the past three years and the biggest for the hot antibody-drug conjugate market.

December 12, 2023
·
2 min read
·
Tyler Patchen
Policy

Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge

Following the regulator’s administrative complaint and threat of a lawsuit in federal court, Sanofi has decided to terminate its licensing deal with Maze Therapeutics to avoid a long litigation process.

December 12, 2023
·
2 min read
·
Tristan Manalac
Drug Development

BMS, 2seventy bio Present Abecma Survival Data at ASH Ahead of Adcomm

The FDA decided last month to convene an advisory committee to discuss the companies’ proposed use of Abecma in earlier lines of treatment for multiple myeloma. Data presented Monday at the American Society of Hematology annual meeting provides a clue as to why.

December 12, 2023
·
2 min read
·
Kate Goodwin
Both Autologous and Allogeneic Have a Place as Cell Therapy Market Explodes

As CAR T cell therapies attract significant biopharma investment, experts say there is plenty of space in the growing market for both treatments that use patients’ own cells and for those that rely on donor cells.

December 12, 2023
·
6 min read
·
Kate Goodwin
Tome Biosciences Launches with $213M in Funding, Targets ‘New Era’ of Genomic Medicines

Backed by ARCH Venture Partners and Fujifilm, as well as technology licensed from MIT, Tome is looking to create curative cell and integrative gene therapies.

December 12, 2023
·
2 min read
·
Tyler Patchen
Deals

Webinar: Alternative Funding Strategies to Discuss at JPM

BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer’s Drug Discovery Foundation will discuss alternative financing strategies to consider for 2024. Watch now.

December 12, 2023
·
4 min read
·
BioSpace Insights
Deals

AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchase

With the acquisition, AstraZeneca will gain access to Icosavax’s investigational combination vaccine IVX-A12, which is being developed for respiratory syncytial virus and human metapneumovirus in older adults.

December 12, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA

In this episode we dive into regulation, real-time management, and AI’s various applications and how it can streamline different processes with guests from Microsoft and IQVIA.

December 12, 2023
·
1 min read
·
BioSpace Insights